Aby Abraham

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3638955/publications.pdf

Version: 2024-02-01

127 papers	1,294 citations	430874 18 h-index	414414 32 g-index
129 all docs	129 docs citations	129 times ranked	1926 citing authors

#	Article	IF	Citations
1	Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data. Journal of Clinical Oncology, 2010, 28, 3866-3871.	1.6	235
2	Acute myeloid leukaemia: challenges and real world data from India. British Journal of Haematology, 2015, 170, 110-117.	2.5	96
3	Improved Clinical Outcomes of High Risk Î² Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. PLoS ONE, 2013, 8, e61637.	2.5	78
4	Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children. Annals of Hematology, 2016, 95, 1429-1434.	1.8	56
5	Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood, 2012, 119, 3413-3419.	1.4	45
6	Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics, 2012, 13, 269-282.	1.3	43
7	Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. PLoS ONE, 2015, 10, e0121912.	2.5	43
8	RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics, 2015, 16, 877-890.	1.3	41
9	Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. Cytometry Part B - Clinical Cytometry, 2012, 82B, 252-258.	1.5	36
10	Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. European Journal of Clinical Pharmacology, 2012, 68, 1577-1586.	1.9	29
11	The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. Cancer Genetics and Cytogenetics, 2010, 203, 297-302.	1.0	27
12	Clinical Profile and Outcomes of Patients with Î² Thalassemia Major and Hepatitis C Virus Infection Undergoing an Allogeneic Stem Cell Transplant. Blood, 2012, 120, 4160-4160.	1.4	27
13	Invasive fungal infection following chemotherapy for acute myeloid leukaemiaâ€"Experience from a developing country. Mycoses, 2017, 60, 686-691.	4.0	26
14	Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Pharmacology and Therapeutics, 2018, 104, 575-583.	4.7	22
15	Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 494-500.	2.0	22
16	Mast cell sarcoma of the small intestine: a case report. Journal of Clinical Pathology, 2011, 64, 1035-1037.	2.0	21
17	Dendritic Cell Count in the Graft Predicts Relapse in Patients with Hematologic Malignancies Undergoing an HLA-Matched Related Allogeneic Peripheral Blood Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2010, 16, 854-860.	2.0	20
18	Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. Leukemia and Lymphoma, 2012, 53, 103-109.	1.3	19

#	Article	IF	Citations
19	The use of a fludarabineâ€based conditioning regimen in patients with severe aplastic anemia â€“ a retrospective analysis from three <scp>I</scp>ndian centers. Clinical Transplantation, 2013, 27, 923-929.	1.6	19
20	Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, e31-e35.	2.0	18
21	Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India. Journal of Global Oncology, 2017, 3, 773-781.	0.5	15
22	Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. Frontiers in Immunology, 2018, 9, 1357.	4.8	14
23	Molecular Characterization of G6PD Deficiency: Report of Three Novel G6PD Variants. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 349-355.	0.6	14
24	A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Cancer Medicine, 2020, 9, 2603-2610.	2.8	14
25	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis, 2021, 121, 1400-1408.	3.4	14
26	Management of relapse in acute promyelocytic leukaemia treated with upâ€front arsenic trioxideâ€based regimens. British Journal of Haematology, 2021, 192, 292-299.	2.5	13
27	Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country. Journal of Global Oncology, 2018, 4, 1-12.	0.5	12
28	NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance. Blood, 2013, 122, 1455-1455.	1.4	12
29	Clinicopathological features of hepatosplenic T cell lymphoma: a single centre experience from India. Leukemia and Lymphoma, 2012, 53, 609-615.	1.3	11
30	Drugâ€resistant organisms are common in fecal surveillance cultures, predict bacteremia and correlate with poorer outcomes in patients undergoing allogeneic stem cell transplants. Transplant Infectious Disease, 2020, 22, e13273.	1.7	11
31	Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantationâ€”A Single Centre Experience. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 215-222.	0.6	10
32	Prognostic plasma biomarkers of early complications and graftâ€versusâ€host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. EJHaem, 2020, 1, 219-229.	1.0	10
33	Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2018, 24, 103-108.	2.0	9
34	Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population. Haemophilia, 2019, 25, 67-74.	2.1	9
35	Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients. Scientific Reports, 2020, 10, 20640.	3.3	9
36	Outcome of treatment with a low cost protocol in adults with T cell acute lymphoblastic leukemia in a tertiary care center in India. Leukemia and Lymphoma, 2014, 55, 947-949.	1.3	8

#	Article	IF	Citations
37	The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 126-134.	0.9	8
38	Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance. Blood, 2012, 120, 1390-1390.	1.4	8
39	Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia. Blood Cancer Journal, 2022, 12, 22.	6.2	8
40	Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. Blood Cells, Molecules, and Diseases, 2017, 66, 37-46.	1.4	7
41	Allogeneic stem cell transplantation for thalassemia major in India. Pediatric Hematology Oncology Journal, 2017, 2, 114-120.	0.1	7
42	Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 71-77.	0.6	7
43	An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia. Transplantation and Cellular Therapy, 2021, 27, 409.e1-409.e6.	1.2	7
44	Acute Myeloid Leukemia: Challenges and Real World Data from India. Blood, 2014, 124, 3685-3685.	1.4	7
45	A Low Incidence of Cytomegalo Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation Despite a High Seroprevalence. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 636-642.	0.6	6
46	Population Pharmacokinetics of Fludarabine and Treosulfan in Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 3120-3120.	1.4	6
47	Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complicationsâ€“A single center experience from India. Transplantation and Cellular Therapy, 2022, 28, 45.e1-45.e8.	1.2	6
48	BK polyomavirus hemorrhagic cystitis in hematopoietic cell transplant recipients. Journal of Global Infectious Diseases, 2022, 14, 17.	0.5	6
49	Role of endovascular embolization in treatment of acute bleeding complications in haemophilia patients. British Journal of Radiology, 2016, 89, 20151064.	2.2	5
50	AtypicalBCR-ABL1fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. Leukemia and Lymphoma, 2016, 57, 2481-2484.	1.3	5
51	Management of Hemophilic Cysts and Pseudotumors ofÂthe Hand in Bleeding Disorders: A Case Series. Journal of Hand Surgery, 2018, 43, 486.e1-486.e9.	1.6	5
52	Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD). Indian Journal of Hematology and Blood Transfusion, 2019, 35, 223-232.	0.6	5
53	Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia. International Journal of Laboratory Hematology, 2021, 43, 658-663.	1.3	5
54	Adrenal incidentaloma caused by extramedullary haematopoiesis: conservative management is optimal. BMJ Case Reports, 2015, 2015, bcr2015211014.	0.5	5

#	Article	IF	Citations
55	Outcomes Following Allogeneic Stem Cell Transplantation Using Non-sibling Family Donors. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 43-49.	0.6	4
56	Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. British Journal of Haematology, 2020, 189, 269-278.	2.5	4
57	Prognostic value of MRD monitoring based onBCR-ABL1copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 3468-3475.	1.3	4
58	Higher Incidence of Graft Rejection in Non-Sibling Fully Matched Related Donor Stem Cell Transplants for Thalassemia Major: A Cautionary Note. Blood, 2018, 132, 2178-2178.	1.4	4
59	Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 615-622.	0.6	4
60	Outcome of iron reduction therapy in ex-thalassemics. PLoS ONE, 2021, 16, e0238793.	2.5	3
61	Clinicogenetic Profile, Treatment Modalities, and Mortality Predictors of Gaucher Disease: A 15-Year Retrospective Study. Public Health Genomics, 2021, 24, 1-10.	1.0	3
62	Very Long Term Follow-up Data of Pediatric Acute Promyelocytic Leukemia Treated with Upfront Arsenic-Trioxide Based Regimens. Blood, 2018, 132, 1400-1400.	1.4	3
63	Clinical and Molecular Characterization of Fanconi Anemia: An Indian Perspective. Blood, 2014, 124, 2938-2938.	1.4	3
64	Management of Relapse in Acute Promyelocytic Leukemia Treated with Upfront Arsenic Trioxide Based Regimens. Blood, 2018, 132, 666-666.	1.4	3
65	Molecular basis of <scp>W</scp>iskottâ€“<scp>A</scp>ldrich syndrome in patients from India. European Journal of Haematology, 2012, 89, 356-360.	2.2	2
66	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 130-135.e1.	0.4	2
67	Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. British Journal of Haematology, 2020, 188, 930-934.	2.5	2
68	Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	2
69	Haplo-Identical Transplants Using Post Transplant Cyclophosphamide (PTCy) Are Associated with Good Outcomes If Transplanted with Early Disease - a Single Centre Analysis from India. Blood, 2018, 132, 4652-4652.	1.4	2
70	Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate â€" Recombinant Factor VIII Fc (Eloctateâ„¢) â€" a Report from India. Blood, 2018, 132, 2494-2494.	1.4	2
71	A 5'UTR Polymorphism in NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen. Blood, 2016, 128, 984-984.	1.4	2
72	Impact of donor telomere length on survival in patients undergoing matched sibling donor transplantation for aplastic anaemia. British Journal of Haematology, 2022, 196, 724-734.	2.5	2

#	Article	IF	Citations
73	Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors. Blood, 2012, 120, 1446-1446.	1.4	2
74	Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning. Transplantation and Cellular Therapy, 2022, 28, 356.e1-356.e6.	1.2	2
75	Ageâ€stratified adenoâ€associated virus serotype 3 neutralizing and total antibody prevalence in hemophilia A patients from India. Journal of Medical Virology, 2022, 94, 4542-4547.	5.0	2
76	Genetic modifiers of secondary iron overload in beta thalassemia major. Blood Cells, Molecules, and Diseases, 2015, 54, 242-243.	1.4	1
77	Pseudotumour of the Mandible Associated with von Willebrandâ€™s Disease. Journal of Maxillofacial and Oral Surgery, 2015, 14, 417-420.	1.4	1
78	Safety of peripheral blood stem cell harvest in children under anaesthesia in the day care setting â€“ A single centre experience. Transfusion and Apheresis Science, 2021, 60, 102962.	1.0	1
79	Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphomaâ€”A Single Center Experience. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 290-298.	0.6	1
80	Trough Level of First Dose of Busulfan (Cmin1) Is a Stronger Predictor of Graft Rejection Than Steady State Concentration (Css1) In Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 518-518.	1.4	1
81	NPM1 Mutated AML Is Associated With Lower Expression Of Poor Prognostic Markers BAALC, ERG and MN1 In Adult Patients With Acute Myeloid Leukaemia. Blood, 2013, 122, 4945-4945.	1.4	1
82	Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score. Blood, 2015, 126, 2620-2620.	1.4	1
83	Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition. Blood, 2016, 128, 446-446.	1.4	1
84	V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia. Indian Journal of Pathology and Microbiology, 2015, 58, 62.	0.2	1
85	Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring. Blood, 2015, 126, 4322-4322.	1.4	1
86	Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience. Blood, 2015, 126, 4386-4386.	1.4	1
87	Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia. Blood, 2019, 134, 3272-3272.	1.4	1
88	Real World Data of Concurrent Arsenic Trioxide and All-Trans Retinoic Acid with Minimal Use of Anthracycline in the Treatment of Acute Promyelocytic Leukemia. Blood, 2021, 138, 2338-2338.	1.4	1
89	Haploidentical Natural Killer Cell Therapy As an Adjunct to Stem Cell Transplantation for Refractory Acute Myeloid Leukemia. Blood, 2021, 138, 3827-3827.	1.4	1
90	Laboratory characterization of obligate carriers of type 3 von Willebrand disease with a potential role for Platelet Function Analyzer (PFAâ€200). International Journal of Laboratory Hematology, 2022, , .	1.3	1

#	Article	IF	Citations
91	Management of a patient with a true popliteal artery aneurysm, mild hemophilia A and low titre inhibitor. Indian Journal of Thoracic and Cardiovascular Surgery, 2013, 29, 248-249.	0.6	0
92	NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1303-1313.	0.7	0
93	Allogeneic Transplant In Children with Severe Aplastic Anemia â€“ Excellent Outcomes with the Use of a Fludarabine Based Conditioning Regimen. Blood, 2010, 116, 3519-3519.	1.4	0
94	Evaluation of Mechanisms of Resistance to Arsenic Trioxide In Patients with Acute Promyelocytic Leukemia. Blood, 2010, 116, 2746-2746.	1.4	0
95	Response to Immunosuppressive Therapy with Antithymocyte Globulin (ATG) In Older Patients with Aplastic Anemia. Blood, 2011, 118, 4374-4374.	1.4	0
96	Improved Clinical Outcomes of High Risk Î² Thalassemia Major Patients Under Going a HLA Matched Related Allogeneic Stem Cell Transplant with the Use of a Treosulphan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. Blood, 2011, 118, 1017-1017.	1.4	0
97	Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML,. Blood, 2011, 118, 3481-3481.	1.4	0
98	Carbonyl Reductase 1 Expression and Polymorphisms Influence Daunorubicin Metabolism in AML. Blood, 2011, 118, 2484-2484.	1.4	0
99	Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data. Blood, 2011, 118, 947-947.	1.4	0
100	Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy. Blood, 2011, 118, 941-941.	1.4	0
101	RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia.. Blood, 2012, 120, 2785-2785.	1.4	0
102	A Phase II Study Using Post-Transplant Cyclophosphamide (PTC) As Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergoing HLA Matched Sibling Donor Stem Cell Transplant (SCT) for Severe Aplastic Anemia (SAA). Blood, 2012, 120, 4199-4199.	1.4	0
103	Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors. Blood, 2012, 120, 3380-3380.	1.4	0
104	Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients. Blood, 2012, 120, 3607-3607.	1.4	0
105	ABC Transporter Expression in Acute Myeloid Leukemia: Association with in Vitro Cytotoxicity and Prognostic Markers. Blood, 2012, 120, 1438-1438.	1.4	0
106	Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission. Blood, 2012, 120, 3552-3552.	1.4	0
107	Delay In Onset Of First Transfusion and Increased Risk Of Graft Rejection In Î² Thalassemia Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant. Blood, 2013, 122, 701-701.	1.4	0
108	Clinical Profile and Outcome Of Patients With Graft Rejection Following Related HLA Matched Allogeneic Stem Cell Transplant For Î² Thalassemia Major. Blood, 2013, 122, 4546-4546.	1.4	0

#	Article	IF	Citations
109	Population Pharmacokinetics of Daunorubicin in AML: Influence on Clinical Outcome. Blood, 2014, 124, 902-902.	1.4	0
110	Proteasome Activity Is Dispensable for the Degradation of PML-RARÎ±: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia. Blood, 2014, 124, 3741-3741.	1.4	0
111	The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation â€“ a Phase II Study. Blood, 2014, 124, 2455-2455.	1.4	0
112	Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India. Blood, 2014, 124, 2462-2462.	1.4	0
113	Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3884-3884.	1.4	0
114	Molecular Basis of Von Willebrand Disease in Patients from India. Blood, 2015, 126, 1102-1102.	1.4	0
115	Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India. Blood, 2015, 126, 3219-3219.	1.4	0
116	Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India. Blood, 2015, 126, 3732-3732.	1.4	0
117	Multi-Drug Resistant Organisms Are Common in Fecal Surveillance Cultures and Do Not Predict Bacteremia but Correlate with Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplants. Blood, 2016, 128, 3406-3406.	1.4	0
118	Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan Based Conditioning Regimen. Blood, 2016, 128, 2201-2201.	1.4	0
119	Role of Pre-Transplant Cardiac and Hepatic T2* Magnetic Resonance for Risk Assessment in Patients with Thalassemia Major Undergoing an Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 2200-2200.	1.4	0
120	Iron Reduction Therapy in Ex-Thalassemics - Long Term Outcome. Blood, 2018, 132, 4591-4591.	1.4	0
121	Targeted IV Vs Oral Busulfan in Very Young Children with Thalassemia Major Undergoing Matched Allogeneic Haematopoietic Stem Cell Transplantation. Blood, 2018, 132, 5707-5707.	1.4	0
122	Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts. Blood, 2019, 134, 4537-4537.	1.4	0
123	Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT. Blood, 2019, 134, 1977-1977.	1.4	0
124	Yttrium-90 Synovectomy in Hemophilic Arthropathy: An Institutional Experience for 15 Years. Indian Journal of Nuclear Medicine, 2020, 35, 143-146.	0.3	0
125	Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India. Blood, 2021, 138, 1105-1105.	1.4	0
126	Endothelial Activation and Stress Index (EASIX) Measured Pre-Transplant Identifies a Subgroup with High Transplant Related Mortality in Patients with Thalassemia Undergoing Stem Cell Transplantation Using Thiotepa-Treosulfan-Fludarabine Conditioning. Blood, 2021, 138, 1781-1781.	1.4	0

#	Article	IF	Citations
127	Ehl Factors at Lower Than Standard Dose Achieve Satisfactory Surgical Haemostatsis in Haemophilia. Blood, 2020, 136, 25-26.	1.4	0